These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16989928)

  • 1. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients.
    Aucoin MW; Wassersug RJ
    Soc Sci Med; 2006 Dec; 63(12):3162-73. PubMed ID: 16989928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eunuchs in contemporary society: characterizing men who are voluntarily castrated (part I).
    Johnson TW; Brett MA; Roberts LF; Wassersug RJ
    J Sex Med; 2007 Jul; 4(4 Pt 1):930-45. PubMed ID: 17627740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer.
    Walker LM; Robinson JW
    J Sex Marital Ther; 2010; 36(2):154-65. PubMed ID: 20169495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy.
    Wibowo E; Wassersug RJ
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):224-38. PubMed ID: 23484454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.
    Gray RE; Wassersug RJ; Sinding C; Barbara AM; Trosztmer C; Fleshner N
    Can J Urol; 2005 Aug; 12(4):2755-63. PubMed ID: 16197599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer.
    Navon L; Morag A
    Soc Sci Med; 2004 Jun; 58(11):2337-47. PubMed ID: 15047089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An active sex life is possible for men undergoing androgen deprivation therapy for prostate cancer].
    Fode M; Østergren P; Jensen CF; Azawi N; Frey A; Sønksen J
    Ugeskr Laeger; 2015 Jun; 177(24):. PubMed ID: 26058525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eunuchs in contemporary society: expectations, consequences, and adjustments to castration (part II).
    Brett MA; Roberts LF; Johnson TW; Wassersug RJ
    J Sex Med; 2007 Jul; 4(4 Pt 1):946-55. PubMed ID: 17627741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications of androgen deprivation therapy in prostate cancer.
    Schwandt A; Garcia JA
    Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.